Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha 2a treatment

Mederacke, Ingmar; Yurdaydin, Cihan; Dalekos, George; Bremer, Birgit; Erhardt, Andreas; Cakaloglu, Yilmaz; YALÇIN, KENDAL; GÜREL, SELİM; Zeuzem, Stefan; Zachou, Kalliopi; BOZKAYA, HAKAN; Dienes, Hans; Manns, Michael; Wedemeyer, Heiner

doi:10.3851/imp1926

Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha 2a treatment

Mederacke I., Yurdaydin C., Dalekos G. N., Bremer B., Erhardt A., Cakaloglu Y., ...Daha Fazla

ANTIVIRAL THERAPY, cilt.17, sa.2, ss.305-312, 2012 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 17 Sayı: 2
Basım Tarihi: 2012
Doi Numarası: 10.3851/imp1926
Dergi Adı: ANTIVIRAL THERAPY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.305-312
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background: The role of anti-HDV immunoglobulin M (IgM) testing in patients receiving pegylated interferon-alpha therapy for hepatitis delta is unknown. We performed anti-HDV IgM testing in a well defined cohort of HDVinfected patients who were treated with pegylated interferon-alpha 2a plus adefovir, or either drug alone.